ArticleMemorias do Instituto Oswaldo Cruz2016
Novel point mutations in the ERG11 gene in clinical isolates of azole resistant Candida species.
Article in Memorias do Instituto Oswaldo Cruz, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- First Case of Candidemia With Fluconazole-ResistantCase reports in infectious diseases · 2026Article
- Genomic Insights ofOpen forum infectious diseases · 2026Review
- Azole resistance: patterns of amino acid substitutions in Candida sterol 14α-demethylase.Antonie van Leeuwenhoek · 2025Article
- Detection of ERG11 gene mutation in coding and non-coding regions of clinical Candida glabrata (Nakaseomyces glabratus) isolates from Pakistan.Access microbiology · 2025Article
- Article
- In vitro antifungal activities of medicinal plants used for treatment of candidiasis in Pader district, Northern Uganda.Tropical medicine and health · 2024Article
- Molecular Evaluation of the mRNA Expression of theJournal of fungi (Basel, Switzerland) · 2024Article
- Review
- Molecular Cloning, Heterologous Expression, Purification, and Evaluation of Protein-Ligand Interactions of CYP51 ofBiomedicines · 2023Article
- Review
- Prevalence and Antifungal Susceptibility of Clinically RelevantTropical medicine and infectious disease · 2022Article
- Lack of Association between Fluconazole Susceptibility andJournal of fungi (Basel, Switzerland) · 2022Article
- The effect of antifungal resistance development on the virulence of Candida species.FEMS yeast research · 2022Article
- Experimental and in-host evolution of triazole resistance in human pathogenic fungi.Frontiers in fungal biology · 2022Review
- Review
- First Genome Sequences of Two Multidrug-ResistantFrontiers in microbiology · 2020Article
- Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility inJournal of fungi (Basel, Switzerland) · 2019Review
- Microevolution of the pathogenic yeastsMicrobial cell (Graz, Austria) · 2019Review
- The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors.Frontiers in microbiology · 2019Review
- Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next generation sequencing.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The azoles are the class of medications most commonly used to fight infections caused by Candida sp. Typically, resistance can be attributed to mutations in ERG11 gene (CYP51) which encodes the cytochrome P450 14α-demethylase, the primary target for the activity of azoles. The objective of this study was to identify mutations in the coding region of theERG11 gene in clinical isolates of Candida species known to be resistant to azoles. We identified three new synonymous mutations in the ERG11 gene in the isolates of Candida glabrata (C108G, C423T and A1581G) and two new nonsynonymous mutations in the isolates of Candida krusei--A497C (Y166S) and G1570A (G524R). The functional consequence of these nonsynonymous mutations was predicted using evolutionary conservation scores. The G524R mutation did not have effect on 14α-demethylase functionality, while the Y166S mutation was found to affect the enzyme. This observation suggests a possible link between the mutation and dose-dependent sensitivity to voriconazole in the clinical isolate of C. krusei. Although the presence of the Y166S in phenotype of reduced azole sensitivity observed in isolate C. krusei demands investigation, it might contribute to the search of new therapeutic agents against resistant Candida isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.